Background: Approximately 20%–50 % of individuals with autoimmune encephalitis (AE) demonstrate suboptimal responses to first-line therapies. leading to persistent neurological deficits and the need for second-line interventions. Although rituximab has shown potential as an alternative treatment in AE. the existing evidence remains insufficient. https://miamistares.shop/product-category/seat-products/